COPENHAGEN, Denmark, May 22, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has dosed the first patient in ...
Evaxion Biotech A/S has announced promising new data on its personalized cancer vaccine, EVX-01, highlighting that 80% of the vaccine's targets elicited a tumor-specific immune response, significantly ...
Evecxia Therapeutics Reports No Toxicology Findings in Nonclinical GLP Studies of Adjunctive EVX-101
- Oral EVX-101 administration over 3 months was modeled in rats and pigs co-treated with the first-line antidepressant fluoxetine. - There were no toxicological findings in either species, even at ...
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Evecxia Therapeutics—the first company dedicated to realizing the therapeutic potential of Serotonin Synthesis Amplification to treat central nervous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results